- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00031993
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the antitumor cytostatic activity of OSI-774 as measured by the probability of surviving progression-free for at least 6 months in patients with persistent or recurrent squamous cell carcinoma of the cervix.
II. To determine the nature and degree of toxicity of OSI-774 in this cohort of patients.
SECONDARY OBJECTIVES:
I. To determine the partial and complete response rates in patients with squamous cell carcinoma of the cervix receiving OSI-774.
II. To determine the duration of progression-free survival and overall survival within this patient population treated with OSI-774.
III. Assess the effects of prognostic factors: initial performance status and age.
TERTIARY OBJECTIVES:
I. To determine epidermal growth factor receptor (EGFR) and p110 truncated EGFR (p110 sEGFR) isoform expression levels in primary tumors, and from tumor samples obtained pretreatment and following four weeks of therapy to determine tumor response (or resistance) to OSI-774 inhibition of the EGFR tyrosine kinase.
II. To correlate EGFR and p110sEGFR expression levels with either MAPK or AKT phosphorylation status in the same tissue samples obtained pretreatment and following four weeks of drug treatment to determine downstream effects with response to OSI-774 inhibition of EGFR.
III. To determine whether pretreatment serum p110 sEGFR concentrations are a useful prognostic indicator and whether altered and/or sEGFR concentrations are useful indicators of therapeutic responsiveness, time to progression, and overall survival in cervical carcinoma patients.
OUTLINE: This is a multicenter study.
Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Gynecologic Oncology Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed squamous cell carcinoma (SCC) of the cervix
- Persistent or recurrent progressive disease
At least 1 prior systemic chemotherapy regimen for management of advanced, metastatic, or recurrent SCC of the cervix is required
- Chemotherapy administered as a radiosensitizer in conjunction with radiotherapy does not count as a systemic chemotherapy regimen
At least 1 unidimensionally measurable target lesion
- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- Lesions within a previously irradiated field are considered nontarget lesions unless disease progression or persistence is confirmed ≥ 90 days after completion of radiotherapy
- Tumor accessible for repeat needle biopsy
- Ineligible for a higher priority Gynecologic Oncology Group (GOG) protocol (any active GOG phase III protocol for the same patient population)
- Performance status - GOG 0-2 (for patients who have received only 1 prior regimen)
- Performance status - GOG 0-1 (for patients who have received 2 prior regimens)
- Platelet count at least 100,000/mm^3
- Absolute neutrophil count at least 1,500/mm^3
- Bilirubin no greater than upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
- Creatinine no greater than 1.5 times ULN
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No abnormalities of the cornea (e.g., dry eye syndrome or Sjogren's syndrome)
- No congenital abnormalities (e.g., Fuch's dystrophy)
- No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
- No abnormal corneal sensitivity test (Schirmer test or similar tear production test)
- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
- No uncontrolled concurrent illness
- No ongoing or active infection requiring IV antibiotics
- No psychiatric illness or social situation that would preclude study compliance
- No grade 2 or greater sensory or motor neuropathy
- No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- At least 3 weeks since prior immunologic therapy for SCC of the cervix
- One additional prior cytotoxic chemotherapy regimen for recurrent or persistent disease allowed
- At least 3 weeks since prior chemotherapy for SCC of the cervix and recovered
- No prior non-cytotoxic chemotherapy for recurrent or persistent disease
- At least 3 weeks since prior hormonal therapy for SCC of the cervix
- At least 3 weeks since prior radiotherapy for SCC of the cervix and recovered
- Recovered from recent prior surgery
- At least 3 weeks since other prior therapy for SCC of the cervix
- No prior epidermal growth factor receptor-targeting therapies
- No prior anticancer treatment that would preclude study participation
- No other concurrent investigational or commercial agents or therapies for SCC of the cervix
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (erlotinib hydrochloride)
Patients receive oral erlotinib once daily for 4 weeks.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival
Time Frame: At 6 months
|
At 6 months
|
Frequency and severity of adverse effects as measured by NCI CTC version 3.0
Time Frame: Up to 5 years
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of overall survival
Time Frame: Up to 5 years
|
Up to 5 years
|
Duration of progression-free survival
Time Frame: Up to 5 years
|
Up to 5 years
|
Frequency of clinical response (complete and partial)
Time Frame: Up to 5 years
|
Up to 5 years
|
Prognostic factors including initial performance status and age
Time Frame: Up to 5 years
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Squamous Cell
- Carcinoma
- Recurrence
- Carcinoma, Squamous Cell
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
Other Study ID Numbers
- NCI-2012-02457
- U10CA027469 (U.S. NIH Grant/Contract)
- GOG-0227D
- CDR0000069247 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Squamous Cell Carcinoma
-
Peking University Third HospitalNot yet recruitingCervical Squamous Cell CarcinomaChina
-
Peking University Third HospitalNot yet recruitingCervical Squamous Cell CarcinomaChina
-
Zhujiang HospitalUnknownStudy of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerNeoplasms | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Cervical Adenosquamous Cell Carcinoma | Cervical Squamous Cell Carcinoma in SituChina
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Persistent DiseaseUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Advaxis, Inc.CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical CarcinomaUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedCervical Squamous Cell Carcinoma | Recurrent Cervical CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Inovio PharmaceuticalsCompletedCervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSILUnited States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage III Cervical Cancer AJCC v6 and v7 | Stage IB Cervical Cancer AJCC v6 and v7United States, Canada
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States